1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Japan >
  5. Moderna Acquires OriCiro Genomics

M&A Deal Summary

Moderna Acquires OriCiro Genomics

On January 4, 2023, Moderna acquired life science company OriCiro Genomics

Acquisition Highlights
  • This is Moderna’s 1st transaction in the Life Science sector.
  • This is Moderna’s 1st transaction in Japan.

M&A Deal Summary
Date 2023-01-04
Target OriCiro Genomics
Sector Life Science
Buyer(s) Moderna
Deal Type Add-on Acquisition

Target

OriCiro Genomics

Tokyo, Japan
OriCiro Genomics is focused on development and commercialization of cell-free synthesis and amplification of plasmid DNAs for applications in gene/cell-based therapies and synthetic biology. OriCiro Genomics was founded in 2018 and is based in Tokyo, Japan.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Moderna

Cambridge, Massachusetts, United States
Category Company
Founded 2010
Sector Life Science
Employees5,800
Revenue 3.2B USD (2024)
DESCRIPTION

Moderna is a life science company focused on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines to direct the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. Moderna was founded in 2010 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Japan M&A 1 of 1
Year: 2023 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal